HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brand-Blinding Needed In Comparison Studies, WaterWipes Told In Review Of Baby Wipe Claim

Firm Qualifies '#1 Clinically Proven' Claim After NAD Review On Kimberly-Clark Challenge

Executive Summary

NAD says firm's superiority and establishment claims should be removed from marketing. WaterWipes relied on results from “Baby Skin Integrity Comparison Survey” published in Journal of Pediatrics and Neonatology, but NAD agreed with challenger Kimberly-Clark that not blinding the brands from study subjects weakened the results.

You may also be interested in...



Over the Counter 29 June 2022: OTC Birth Control In The Wake Of The US Supreme Court Decision With Victoria Nichols

In this episode, HBW Insight speaks to Victoria Nichols, project director of Free the Pill, a campaign supporting increased OTC oral contraceptive access in the US. In the wake of the Supreme Court’s decision to overturn Roe v. Wade on 24 June, Nichols discusses the importance of advocating for OTC birth control, the limited availability of OTC oral contraceptives in the US, and the current legislation being introduced that would help ensure OTC birth control is covered by insurance. 

After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway

Publication of "ACNU" proposed rule wasn’t reached in straight line and featured coining another term with more of a regulatory sound, “NSURE,” and detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.

USPSTF Doesn’t See Forest Of VMS Benefits For Trees Of Reducing Cancer, Heart Disease Risks

US Preventative Services Task Force concludes evidence doesn't support  recommending VMS use to prevent cancer or cardiovascular disease. Trade groups and a natural medicine expert say task force's focus is narrow and its recommendation misleading. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel